We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
AFT Pharmaceuticals is a drug manufacturers-specialty & generic business based in Australia. AFT Pharmaceuticals shares (AFP) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. AFT Pharmaceuticals has a trailing 12-month revenue of around $119.8 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $3.64 - $4.8 |
|---|---|
| 50-day moving average | $4.1704 |
| 200-day moving average | $4.1493 |
| Target price | N/A |
| PE ratio | 39.5049 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.101 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$3.99
| 1 week (2022-01-17) | 1.53% |
|---|---|
| 1 month (2021-12-24) | 1.53% |
| 3 months (2021-10-22) | 2.31% |
| 6 months (2021-07-23) | -8.28% |
| 1 year (2021-01-22) | -11.53% |
|---|---|
| 2 years (2020-01-24) | 28.71% |
| 3 years (2019-01-24) | 102.03% |
| 5 years (2017-01-24) | 53.46% |
Valuing AFT Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AFT Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AFT Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, AFT Pharmaceuticals shares trade at around 40x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AFT Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.1 million (£0.0 million).
The EBITDA is a measure of a AFT Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $119.8 million |
|---|---|
| Operating margin TTM | 11.5% |
| Gross profit TTM | $48.7 million |
| Return on assets TTM | 8.62% |
| Return on equity TTM | 30.52% |
| Profit margin | 9.04% |
| Book value | 0.387 |
| Market capitalisation | $417.7 million |
TTM: trailing 12 months
We're not expecting AFT Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, AFT Pharmaceuticals's shares have ranged in value from as little as $3.64 up to $4.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while AFT Pharmaceuticals's is 0.099. This would suggest that AFT Pharmaceuticals's shares are less volatile than average (for this exchange).
AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail and oral care, pain management, skin care, and other products, as well as supplements. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.
It can be confusing knowing the difference between a KN95 and N95 face mask. We look at them both and where to buy them online.
Here’s what Ryan Edwards-Pritchard learned so far about building a startup in the grips of a pandemic.
Arsenal and Liverpool are locked at 0-0 ahead of their Carabao Cup semi-final second leg this week.
Heres how stock levels and prices are holding up for RATs in Australia.
Learn how to stake OHM and receive high yield from one of DeFi's most ambitious experiments.
Being early to a new DeFi ecosystem can be very profitable – here's how to game the system and potentially earn yourself some tokens.
Reporting season is a 2-week or so period where investors can see the results for a large number of publicly traded companies.
Bank First’s variable rate green personal loan can be used to make environmentally friendly purchases for your home.
The 10 biggest movers on the ASX for Thursday 20 January 2022.
